Clinical trials
Oligometastases clinical trials
Below are recruiting oligometastases clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07415356Recruiting
Adaptive radiation for lymph node tumors that have spread
This trial tests a new way to deliver targeted radiation for cancer that has spread to lymph nodes in the belly or pelvis. The radiation dose is adjusted during each session to better hit the tumor while protecting healthy tissue.
Rotterdam, South HollandAges 18 years+ - NCT06542159RecruitingPhase 2
Adaptive radiation for early-stage lung cancer or small metastases
This trial tests a more precise radiation technique (stereotactic body radiotherapy) for early-stage lung cancer or small lung tumors. It aims to reduce side effects by eliminating the usual safety margin around the tumor.
Guangzhou, GuangdongAges 18 years+ - NCT06850103RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced rectal cancer that has spread a little
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT07481799RecruitingPhase 3
Targeted drug plus focused radiation for EGFR-positive cancer that has spread a little
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
Zhuhai, GuangdongAges 18–75 - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT03548428RecruitingPhase 2
Targeted radiation for a small number of sarcoma metastases
This Phase 2 trial tests a highly focused radiation treatment to shrink sarcoma that has spread to a limited number of spots in the body. It may help control disease while limiting radiation to healthier tissue.
BordeauxAges 18 years+ - NCT04075305Recruiting
Study measuring radiation treatment outcomes with an MR-Linac
This study follows what happens when radiation treatment is guided using an MR-Linac (a special machine that combines MRI imaging with radiation). It may help improve how radiation therapy is planned and assessed, especially for people who can safely have MRI scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04805255Recruiting
Study brain-targeted radiation for limited brain metastases
This study looks at people with a small number of brain metastases who are treated with a focused, staged form of radiation after surgery or to treat the cancer. It may help doctors better understand how well this approach works and who benefits most.
TaoyuanAges 18–84 - NCT05990192RecruitingPhase 2
SBRT with or without niraparib for ovarian cancer after PARP inhibitor treatment
This trial tests a new treatment approach for people with ovarian cancer that has started to progress in a few spots (up to 3) after taking a PARP inhibitor. It combines targeted radiation (SBRT) to those spots, followed by another PARP inhibitor (niraparib), to see if this can control the cancer further.
Leeds, LeedsAges 18 years+ - NCT05717166RecruitingPhase 3
Stereotactic radiation for limited metastases with a main tumor
This trial tests whether a precise type of radiation can control cancer that has spread to a limited number of sites (1–10) while you also have the main tumor. It aims to improve outcomes by treating all visible cancer spots with stereotactic ablative radiotherapy.
Prince George, British ColumbiaAges 18 years+ - NCT06135714RecruitingPhase 3
Targeting limited breast cancer spread with focused therapy
This trial tests whether treating just the few spots where breast cancer has spread (called oligometastases) with radiation or surgery can help control the disease. It is for people whose cancer has spread to 3 or fewer places, each small in size, and who are healthy enough for local treatments.
Tokyo, TokyoAges 18–80 - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75
Hear when a new Oligometastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oligometastases?
- Yes. Clin2 currently lists 13 recruiting oligometastases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oligometastases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oligometastases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.